Pharmazz, Inc. Receives U.S. FDA IND Clearance to Initiate Phase 3 Clinical Trial of Sovateltide in Traumatic Brain Injury

A proprietary neural-repair discovery platform reached an unspecified milestone, supporting expansion of a first-in-class endothelin-B receptor agonist into neurotrauma. The development targets a critical indication with significant unmet need and may broaden the therapy's commercial and clinical opportunity, though no trial data, financial terms, or regulatory details were disclosed.